Dual therapeutic interventions to optimize vancomycin exposure and reduce nephrotoxicity: a cohort study from a single center Authors: Janice Xuanhui Li, Horng-Ruey Chua, Gladys Wei-Teng Chung, Jyoti Somani, Yi Da Published: 2026 ABSTRACT BackgroundVancomycin-associated Acute Kidney Injury (AKI) is a significant global concern, increasing healthcare costs, morbidity, and mortality. This Quality Improvement Project (QIP) aimed to reduce supratherapeutic vancomycin concentrations and AKI by lowering the trough target and implementing AUC (Area Under the Curve)-based dosing.MethodsThis was a single-center cohort study. Adult patients receiving intravenous vancomycin for at least 72 h were prospectively recruited from January to June 2022. Vancomycin trough target was revised from 15 to 20 mg/L to 10-20 mg/L, and a hybrid dosing strategy incorporating AUC-based dosing for eligible patients was piloted in five wards. A historical cohort from June to November 2021, managed with higher trough target of 15-20 mg/L, was investigated for comparison. The primary outcome was the rate of supratherapeutic vancomycin trough concentrations (> 20 mg/L). Secondary outcomes included AKI incidence, total vancomycin dose over the initial 72 h, in-hospital mortality, and operational metrics related to therapeutic drug monitoring.ResultsA total of 80 patients in the historical cohort and 57 in the QIP cohort were analysed. The rate of supratherapeutic vancomycin trough concentrations was lower in the QIP cohort compared with the historical cohort (11% vs. 20%, p < 0.01). AKI rate was lower in the QIP cohort, although not statistically significant (12% vs. 18%). In-hospital mortality was numerically lower in the QIP cohort (3.5% vs. 7.5%). The total vancomycin dose administered during the initial 72 h was significantly lower in the QIP cohort (83 [56–100] vs. 104 [76–119] mg/kg, p < 0.01). Vancomycin concentrations were monitored less frequently, while dose adjustments were similar between cohorts.ConclusionLowering the vancomycin trough target and adopting AUC dosing in selected patients reduced supratherapeutic vancomycin concentrations, and showed potential to lower nephrotoxicity, without requiring increased monitoring or dose adjustments. However, the small number of patients receiving AUC-guided dosing limits interpretation of its specific contribution.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12882-026-05024-7. Background Vancomycin-associated Acute Kidney Injury (AKI) is a global concern with reported incidence ranging from 5–43% [1]. This condition leads to prolonged hospital stays, increased healthcare costs, and higher short- and long-term morbidity and mortality [2]. During a urinary biomarker study for drug-induced AKI, we observed a notable incidence of AKI associated with vancomycin use at our institution [3]. This prompted a re-evaluation of our vancomycin dosing practices and the initiation of a Quality Improvement Project (QIP) to explore interventions aimed at safely reducing supratherapeutic vancomycin concentrations and associated nephrotoxicity. Accumulating evidence indicates higher vancomycin trough concentrations are associated with a higher rate of AKI [4, 5], and the previously recommended trough target of 15-20 mg/L has been linked to increased nephrotoxicity [6]. Higher vancomycin area under the concentration curve (AUC), particularly above 650 mg·h/L, is similarly associated with increased AKI [7]. However, trough concentrations do not correlate well with AUC, with more than half of patients achieving AUC>400 mg·h/L despite trough concentrations<15 mg/L [8]. AUC-guided vancomycin dosing targeting an area under the concentration-time curve to the minimum inhibitory concentration (AUC/MIC) of 400–600 has been associated with lower AKI incidence [4, 9, 10]. Current consensus guideline recommends AUC-based dosing for treating serious Methicillin-Resistant Staphylococcus aureus (MRSA) infections [1], and emerging evidence suggests it may be a viable approach for non-MRSA strains too [11, 12]. Taken together, the strategy to reduce vancomycin nephrotoxicity would be to adopt AUC-guided dosing in suitable patients, and to expand the target trough range to 10-20 mg/L based on infection site and severity for those remaining on trough-based monitoring. However, implementation of AUC-guided dosing can be challenging due to workflow changes and additional resources [13–15], as well as the uncertainty about the performance of available AUC calculators in local populations without prior validation [16, 17]. Therefore, we sought to undertake a cohort study embedded within a QIP to evaluate vancomycin dosing strategies, comparing a historical cohort using trough-based dosing with a target of 15–20 mg/L to a QIP cohort implementing a lower trough target of 10–20 mg/L, with incorporation of AUC-guided dosing in selected patients. We compared these dosing methods in terms of vancomycin therapeutic exposure, AKI rate, and to assess the feasibility of implementation. Methods Study design This was a single-center cohort study at a 1200-bed tertiary academic medical centre. The QIP was undertaken in collaboration with Nephrologists, Infectious Disease Physicians, and Clinical Pharmacists. The interventions included a revision of the institutional vancomycin trough target to 10-20 mg/L (Intervention 1) and algorithm-based selection of patients for AUC-guided dosing in pilot wards (Intervention 2). These are described in detail in the subsequent section. All adult patients aged 21 years or older who received intravenous (IV) vancomycin for more than 72 h between 1st January to 30th June 2022 were prospectively recruited; exclusion criteria included patients in whom vancomycin was initiated in the Intensive Care Unit (ICU), pregnant patients, and those on renal replacement therapy at the time of vancomycin initiation. A historical cohort consisting of patients treated between May and November 2021 was retrospectively investigated using the same inclusion and exclusion criteria. The project was approved by the National Healthcare Group Domain Specific Review Board (NHG DSRB 2022/00776) at National University Hospital, Singapore, where the study was conducted. The study was conducted in accordance with the Declaration of Helsinki. A waiver of informed consent was granted. For implementation, 5 wards with MRSA isolation facilities (intended for patients identified as MRSA colonizers via routine screening of axillary, groin, or nasal sites) were designated as pilot wards, where clinical pharmacists with expertise in AUC-guided dosing were deployed. Within the pilot wards, patients were assessed for suitability for AUC-guided dosing based on a predefined algorithm, and not all patients received AUC-based dosing. In the other wards, the revised dosing guideline was implemented, without AUC-guided dosing. This design allowed assessment of the overall impact of the QIP compared to historical practice, with additional analyses examining dosing approaches within the QIP cohort. The study design is illustrated in Fig. 1. Fig. 1The Schematic Representation of the Study Design. The historical cohort consisted of 80 cases that met the inclusion and exclusion criteria between May to November 2021. The QIP took place from January to June 2022. Intervention 1 featured a revision of target vancomycin trough to 10-20 mg/L. Intervention 2 involved an algorithm-based selection of patients for AUC-guided dosing in five pilot wards with AUC-trained pharmacist support. QIP, Quality Improvement Project. AUC, Area Under the Curve The Schematic Representation of the Study Design. The historical cohort consisted of 80 cases that met the inclusion and exclusion criteria between May to November 2021. The QIP took place from January to June 2022. Intervention 1 featured a revision of target vancomycin trough to 10-20 mg/L. Intervention 2 involved an algorithm-based selection of patients for AUC-guided dosing in five pilot wards with AUC-trained pharmacist support. QIP, Quality Improvement Project. AUC, Area Under the Curve Initial vancomycin dosing and serum creatinine monitoring Vancomycin was initiated according to the institutional guidelines at a dose of 15-20 mg/kg (rounded to the nearest 250 mg), with a loading dose of 25-30 mg/kg recommended for patients with severe infections. Dosing frequency was adjusted based on estimated creatinine clearance (CrCl): every 8–12 h for CrCl>50mL/min, once daily for CrCl 30-50mL/min, every 48 h for CrCl 20-30mL/min, and every 2–3 days for CrCl<20mL/min. The initial dosing strategy was the same across all study groups. For trough-based dosing, the trough concentration was obtained within 30 min prior to the third or fourth dose, or at the estimated steady state based on drug clearance and half-life. Once the target trough was achieved, a confirmatory trough could be obtained approximately 48 h later. If concentrations remained stable, subsequent trough monitoring was performed weekly. Serum creatinine was recommended to be monitored at least twice weekly during vancomycin therapy. This served as clinical guidance rather than a mandatory requirement, allowing clinicians to adjust monitoring frequency based on individual patient factors and clinical judgement. QIP interventions Intervention 1: Revision of target vancomycin trough (institution-wide) A revision of the existing institutional protocol for vancomycin dosing was initiated by both the Nephrology and Infectious Disease divisions, under Department of Medicine, and the Department of Pharmacy. The key change was the revision of a widened target range of the vancomycin trough from 15 to 20 mg/L to 10-20 mg/L. This would allow clinicians and pharmacists greater flexibility to adjust vancomycin dosing based on the organism, infection source, and severity, avoiding unnecessary up titration for concentrations below 15 mg/L but still considered therapeutic. Typical examples where troughs of 10-15 mg/L were considered acceptable included uncomplicated urinary tract infections and mild skin or soft tissue infections. For severe infections (e.g., pneumonia, meningitis, endocarditis, osteomyelitis, bacteraemia, septic arthritis, and intra-abdominal infections), the institutional guideline specified a trough target of 15–20 mg/L. The revised vancomycin trough protocol was implemented institution-wide from 1 January 2022. Intervention 2. Adoption of AUC dosing for selected patients (pilot wards) Five wards with MRSA isolation facilities were chosen as pilot wards. Within these pilot wards, patients were assessed for suitability for AUC-guided dosing using a predefined algorithm. Eligible patients included those with confirmed MRSA bacteraemia or those expected to receive IV vancomycin for more than 1 week. Patients with fluctuating renal function (defined as serum creatinine change of > 25% within 3 days) or with serum creatinine > 180µmol/L were excluded from AUC dosing due to concerns regarding the reliability of AUC estimation. Patients with MRSA MIC>1 mg/L were also excluded. The selection algorithm is shown in Fig. 2. Fig. 2The algorithm for patient selection in pilot wards for either AUC dosing or trough dosing. sCr, Serum Creatinine. MRSA, Methicillin-Resistant Staphylococcus aureus; MIC, minimum inhibitory concentration; AUC, Area Under the Curve. C1, Peak Concentration. C2, Trough concentration. TDM, Therapeutic Drug Monitoring. UTI, Urinary Tract Infection. SSTI, Skin and Soft Tissue Infection The algorithm for patient selection in pilot wards for either AUC dosing or trough dosing. sCr, Serum Creatinine. MRSA, Methicillin-Resistant Staphylococcus aureus; MIC, minimum inhibitory concentration; AUC, Area Under the Curve. C1, Peak Concentration. C2, Trough concentration. TDM, Therapeutic Drug Monitoring. UTI, Urinary Tract Infection. SSTI, Skin and Soft Tissue Infection In our protocol, peak concentration (C1) was obtained 2 h after completion of the vancomycin infusion, typically after the 3rd or 4th dose. The trough concentration (C2) was then drawn 30–60 min before the subsequent dose. After AUC was calculated from C1 and C2, a confirmation trough was then obtained approximately 48 h later. Serum creatinine was recommended to be taken together with the confirmation trough, and then monitored twice weekly once the target AUC was achieved. This served as clinical guidance rather than a mandatory requirement for creatinine monitoring. The Society of Infectious Diseases Pharmacists (SIDP) AUC calculator was used [18]. This calculator estimates the patient-specific pharmacokinetic parameters and AUC using two steady-state blood samples and provides recommended dose modification to achieve the target AUC of 400-600 mg·h/L. Once the therapeutic AUC is achieved, an individualised target trough range using proportional relationship between AUC and trough is determined. Subsequent AUC calculations are not required unless there are changes to the drug clearance or volume of distribution for the patient. A core group of pharmacists were trained to use the AUC calculator and deployed to the pilot wards, where they managed the dosing and titration of vancomycin. The patients in the rest of the wards were managed by ward pharmacists using trough-based monitoring according to the 2009 IDSA Consensus Statement on Vancomycin Therapeutic Drug Monitoring (TDM), and using the lowered trough targets. Data collection All data were collected retrospectively by the QIP team, using REDCap electronic data capture tools hosted by the institution from the electronic medical records (Clinical Patient Support System 2, CPSS2; the Next Generation Electronic Medical Record, NGEMR). The dataset included patient demographics, Charlson comorbidity index, baseline serum creatinine, and peak serum creatinine from the start of therapy up to 72 h post-therapy. Information on treatment indication, infection site, causative pathogens, and treatment duration was also collected. In-hospital mortality was recorded. Vancomycin-related data included initial vancomycin dosing, first trough concentrations, total vancomycin dose administered during the initial 72 h, and the distribution of vancomycin troughs categorized as < 10 mg/L (subtherapeutic), 10-20 mg/L (therapeutic), or > 20 mg/L (supratherapeutic) during therapy. Exact concentrations were not recorded for every measurement; rather, all troughs were captured as counts within these categories. The total number of vancomycin concentrations obtained was recorded; for patients receiving AUC-guided dosing, this included both trough and peak concentrations. The total number of dose adjustments during therapy was also recorded. For the QIP cohort, additional information was collected on whether the first dose was a loading dose. Safety-related data were collected to monitor for potential unintended consequences of reduced vancomycin exposure, including the presence of bacteraemia and recurrence of bacteraemia during admission. In our protocol, all patients with bacteraemia had repeat blood cultures drawn. For patients receiving AUC-guided dosing, the calculated AUC values were also recorded. Outcome measurements and definitions The primary outcome of the study was the rate of supratherapeutic vancomycin trough concentration, defined as the proportion of vancomycin trough concentrations exceeding 20 mg/L during the entire treatment course. The rate of subtherapeutic vancomycin trough concentrations (< 10 mg/L) was evaluated as a secondary outcome. Other secondary outcomes included AKI incidence and AKI incidence density. AKI was defined as a rise in serum creatinine of at least 26.5µmol/L within 48 h or a 50% increase from baseline within 7 days while on vancomycin or up to 72 h after cessation. AKI incidence density was calculated as the number of AKI events per 100 vancomycin drug days to account for variation in treatment duration. Table 1 summarises the definitions and calculations of TDM- and AKI-related outcomes. Table 1Definitions and calculation of TDM- and AKI- related outcomesMeasure nameNumeratorDenominatorClinical MeaningRate of supratherapeutic trough concentrationNumber of vancomycin troughs more than 20 mg/L during treatmentTotal number of vancomycin trough concentrations checked during treatmentDescribing the rate of supratherapeutic vancomycin concentration of a cohort. An increase in this prompts concerns on the development of AKI.Rate of subtherapeutic trough concentrationNumber of vancomycin troughs less than 10 mg/L during treatmentTotal number of vancomycin trough concentrations checked during treatmentDescribing the rate of subtherapeutic vancomycin concentration of a cohort. An increase in this prompts concerns of inadequate treatment efficacy for infection.AKI incidenceNumber of patients who develop AKITotal number of patientsDescribing AKI incidence in the study population.AKI per 100 drug-daysNumber of patients who develop AKITotal number of drug days across all patients in the cohort / 100Normalizing the AKI incidence by the duration of drug exposure.AKI, Acute Kidney Injury. TDM, Therapeutic Drug Monitoring Table 1Definitions and calculation of TDM- and AKI- related outcomesMeasure nameNumeratorDenominatorClinical MeaningRate of supratherapeutic trough concentrationNumber of vancomycin troughs more than 20 mg/L during treatmentTotal number of vancomycin trough concentrations checked during treatmentDescribing the rate of supratherapeutic vancomycin concentration of a cohort. An increase in this prompts concerns on the development of AKI.Rate of subtherapeutic trough concentrationNumber of vancomycin troughs less than 10 mg/L during treatmentTotal number of vancomycin trough concentrations checked during treatmentDescribing the rate of subtherapeutic vancomycin concentration of a cohort. An increase in this prompts concerns of inadequate treatment efficacy for infection.AKI incidenceNumber of patients who develop AKITotal number of patientsDescribing AKI incidence in the study population.AKI per 100 drug-daysNumber of patients who develop AKITotal number of drug days across all patients in the cohort / 100Normalizing the AKI incidence by the duration of drug exposure.AKI, Acute Kidney Injury. TDM, Therapeutic Drug Monitoring Definitions and calculation of TDM- and AKI- related outcomes AKI, Acute Kidney Injury. TDM, Therapeutic Drug Monitoring Additional secondary outcomes included the total vancomycin dose administered during the initial 72 h, and in-hospital mortality. Operational outcomes relevant to implementation included the number of vancomycin concentrations obtained per patient per drug day, and the number of dose adjustments per patient per drug day. Sample size calculation Based on the historical cohort of 80 patients, the rate of supratherapeutic vancomycin troughs was 20%. The median treatment duration was 10 days, with 4 to 5 trough concentrations per patient. To detect a reduction in the rate of supratherapeutic troughs to 10%, with 80% power and a two-sided alpha of 0.05, approximately 50 patients were required in the QIP cohort. Statistical analysis Categorical variables were compared between groups using Chi-square or Fisher’s exact tests where appropriate. Non-parametric and parametric variables were compared between two groups using the Mann-Whitney U test and T-test, respectively. Poisson regression was used to examine differences between incidence densities of events between groups. A two-tailed p value < 0.05 was used to determine statistical significance. All statistical analyses were performed using R software version 4.1.1 (2021-08-10). Results One hundred thirty-six patients receiving IV vancomycin were screened for eligibility during the QIP period (Fig. 3). A total of 57 patients were in the QIP cohort, of whom 22 were in the pilot wards, and 9 received AUC-guided dosing based on the predefined selection algorithm. Eighty patients were included in the historical cohort. The QIP and historical cohort were generally similar in terms of patient demographics, comorbidities, and baseline kidney function. However, the median treatment duration was longer in the historical cohort (10 [6–13] days) compared to the QIP cohort (7 [5–13] days). Differences were also observed in the causative organisms. Clinical characteristics are summarized in Table 2. Fig. 3Flow diagram of patient screening and allocation within the prospective QIP cohort. A total of 136 patients receiving IV vancomycin were screened during the QIP period. Of the 57 eligible patients, 22 were in pilot wards, and 35 were in non-pilot wards. In pilot wards, patients were assessed for suitability for AUC-guided dosing using a predefined algorithm. Not all patients in pilot wards received AUC-guided dosing. QIP, Quality Improvement Project; IV, Intravenous; ICU, Intensive Care Unit Flow diagram of patient screening and allocation within the prospective QIP cohort. A total of 136 patients receiving IV vancomycin were screened during the QIP period. Of the 57 eligible patients, 22 were in pilot wards, and 35 were in non-pilot wards. In pilot wards, patients were assessed for suitability for AUC-guided dosing using a predefined algorithm. Not all patients in pilot wards received AUC-guided dosing. QIP, Quality Improvement Project; IV, Intravenous; ICU, Intensive Care Unit Table 2Clinical characteristics of the historical and QIP cohortsHistorical Cohort (n = 80)QIP Cohort (n = 57)DemographicsAge, median year (IQR)67 (16)67 (16)Male (%)45 (56)34 (60)Weight, median kg (IQR)57 (12)58 (18)Charlson Comorbidity Index, median (IQR)5 (4)5 (4)Baseline kidney functionBaseline sCr, median µmol/L (IQR)61 (46)66 (40)CrCl (ml/min) (%)> 6050 (63)38 (67)30–6025 (31)17 (30)10–305 (6)2 (4)Vancomycin indicationCulture-directed use (%)63 (79)42 (74)Source of infection (%) Skin/Soft Tissue 20 (25)11 (19) Bone/joint 7 (9)10 (18) Urinary Tract 15 (19)14 (25) Pneumonia 4 (5)4 (7) Line-related 4 (5)3 (5) Intra-abdominal 12 (15)8 (14) Others* 18 (23)7 (12)Causative organism (%) Methicillin-resistant Staphylococcus aureus (MRSA) 21 (26)12 (21) Coagulase negative Staphylococcus aureus (CONS) 23 (29)6 (11) Enterococcus spp. 10 (13)20 (35) Others or Unknown 26 (33)19 (33)Duration of therapy, median days (IQR)10 (7)7 (8)IQR= Interquartile Range. sCr, Serum Creatinine* Others include Corynebacterium, Bacillus or Streptococcus Table 2Clinical characteristics of the historical and QIP cohortsHistorical Cohort (n = 80)QIP Cohort (n = 57)DemographicsAge, median year (IQR)67 (16)67 (16)Male (%)45 (56)34 (60)Weight, median kg (IQR)57 (12)58 (18)Charlson Comorbidity Index, median (IQR)5 (4)5 (4)Baseline kidney functionBaseline sCr, median µmol/L (IQR)61 (46)66 (40)CrCl (ml/min) (%)> 6050 (63)38 (67)30–6025 (31)17 (30)10–305 (6)2 (4)Vancomycin indicationCulture-directed use (%)63 (79)42 (74)Source of infection (%) Skin/Soft Tissue 20 (25)11 (19) Bone/joint 7 (9)10 (18) Urinary Tract 15 (19)14 (25) Pneumonia 4 (5)4 (7) Line-related 4 (5)3 (5) Intra-abdominal 12 (15)8 (14) Others* 18 (23)7 (12)Causative organism (%) Methicillin-resistant Staphylococcus aureus (MRSA) 21 (26)12 (21) Coagulase negative Staphylococcus aureus (CONS) 23 (29)6 (11) Enterococcus spp. 10 (13)20 (35) Others or Unknown 26 (33)19 (33)Duration of therapy, median days (IQR)10 (7)7 (8)IQR= Interquartile Range. sCr, Serum Creatinine* Others include Corynebacterium, Bacillus or Streptococcus Clinical characteristics of the historical and QIP cohorts IQR= Interquartile Range. sCr, Serum Creatinine * Others include Corynebacterium, Bacillus or Streptococcus The rate of supratherapeutic vancomycin trough concentrations in the QIP cohort was 11%, lower than the 20% observed in the historical cohort (p < 0.01) (Table 3). The rate of subtherapeutic trough concentrations was 17% in the QIP cohort and 12% in the historical cohort, with no statistically significant difference (p = 0.07). AKI occurred in 12% of patients in the QIP cohort, compared with 18% in the historical cohort, although this difference was not statistically significant. To account for differences in treatment duration, AKI per 100 drug days was 1.3 in the QIP cohort versus 1.6 in the historical cohort, with no statistically significant difference. Table 3Outcome measures for historical cohort and QIP cohortHistorical Cohort (n = 80)QIP Cohort (n = 57)p ValuePrimary OutcomeRate of supratherapeutic vancomycin trough* %20%11% < 0.01 Secondary outcomeRate of subtherapeutic vancomycin trough* %12%17% 0.07 AKI incidence (%)14 (18)7 (12) 0.55 AKI per 100 drug days**1.61.3 NS Total dose in the first 72 h (mg/kg), median (IQR)104 (43)83 (44) < 0.01 In-hospital mortality (%)6 (7.5)2 (3.5) 0.54 Operational indicesNumber of vancomycin concentration checked per patient per drug day*, median (IQR)0.52 (0.20)0.49 (0.20) 0.03 Number of dose adjustment per patient per drug day, median (IQR)0.24 (0.21)0.24 (0.18) 0.49 IQR= Interquartile Range; TDM, Therapeutic Drug Monitoring; AKI=Acute Kidney Injury; NS = Not Significant* Three patients in the QIP cohort did not have any vancomycin concentration checked. They were therefore excluded from this part of the study** Poisson analysis used while accounting for the different duration of vancomycin treatment Table 3Outcome measures for historical cohort and QIP cohortHistorical Cohort (n = 80)QIP Cohort (n = 57)p ValuePrimary OutcomeRate of supratherapeutic vancomycin trough* %20%11% < 0.01 Secondary outcomeRate of subtherapeutic vancomycin trough* %12%17% 0.07 AKI incidence (%)14 (18)7 (12) 0.55 AKI per 100 drug days**1.61.3 NS Total dose in the first 72 h (mg/kg), median (IQR)104 (43)83 (44) < 0.01 In-hospital mortality (%)6 (7.5)2 (3.5) 0.54 Operational indicesNumber of vancomycin concentration checked per patient per drug day*, median (IQR)0.52 (0.20)0.49 (0.20) 0.03 Number of dose adjustment per patient per drug day, median (IQR)0.24 (0.21)0.24 (0.18) 0.49 IQR= Interquartile Range; TDM, Therapeutic Drug Monitoring; AKI=Acute Kidney Injury; NS = Not Significant* Three patients in the QIP cohort did not have any vancomycin concentration checked. They were therefore excluded from this part of the study** Poisson analysis used while accounting for the different duration of vancomycin treatment Outcome measures for historical cohort and QIP cohort IQR= Interquartile Range; TDM, Therapeutic Drug Monitoring; AKI=Acute Kidney Injury; NS = Not Significant * Three patients in the QIP cohort did not have any vancomycin concentration checked. They were therefore excluded from this part of the study ** Poisson analysis used while accounting for the different duration of vancomycin treatment The total vancomycin dose administered during the initial 72 h was significantly lower in the QIP cohort (83 [56–100] mg/kg) than in the historical cohort (104 [76–119] mg/kg, p < 0.01), reflecting reduced vancomycin exposure. In terms of safety, in-hospital mortality was 3.5% in the QIP cohort and 7.5% in the historical cohort. Among QIP patients, 21% had bacteraemia at baseline, and no bacteraemia recurrence was observed. With respect to operational indices, the number of vancomycin concentrations obtained per patient per drug day was lower in the QIP cohort (0.49 [0.38–0.58]) compared to the historical cohort (0.52 [0.44–0.64], p = 0.03), while the number of dose adjustments per patient per drug day was similar between cohorts. A three-cohort comparison exploring outcomes across the historical cohort, QIP non-pilot wards, and pilot wards is provided in Supplementary Table 1. These cohorts reflect progressive implementation of the interventions, with the historical cohort representing pre-intervention practice, QIP non-pilot wards reflecting revision of vancomycin trough targets, and pilot wards reflecting additional AUC-guided dosing in selected patients based on a predefined algorithm. The rate of supratherapeutic trough concentrations decreased from 20% in the historical cohort to 12% in non-pilot wards and 9% in pilot wards. AKI incidence was 18%, 14%, and 9%, respectively, with corresponding rates of 1.6, 1.7, and 0.8 per 100 drug days. Within the QIP cohort, 9 patients received AUC-guided dosing, and their characteristics and outcomes are summarised in Supplementary Table 2. These cases represented a selected subgroup identified using the predefined algorithm for AUC-guided dosing, with a median serum creatinine of 102 [66–116] µmol/L, bacteraemia in 33% of patients, MRSA infection in 89% patients, and a treatment duration of 13 [6–13] days. The rate of supratherapeutic trough concentrations in the AUC-guided subgroup was 3%; AKI occurred in 1/9 patients (11%), and there were no in-hospital deaths. From an implementation perspective, the median number of vancomycin concentrations obtained per patient per drug day in the AUC-guided subgroup was 0.42 [0.38–0.52], and the median number of dose adjustments per patient per drug day was 0.15 [0.13–0.17]. For context, the corresponding values in the trough-based subgroup were 0.50 [0.38–0.60] and 0.25 [0.17–0.33], respectively. Further details of the AUC-guided cases are provided in Table 4. Among the 8 patients who achieved the target AUC of 400–600 mg·h/L, 6 (75%) had trough concentrations below 15 mg/L, and the median trough associated with an AUC > 400 mg·h/L was 13.7 mg/L. Table 4Characteristics and vancomycin dosing of patients monitored by AUCAge (years)Weight (kg)Baseline Serum Creatinine (µmol/L)AUC (mg·h/L)Dose RegimenTrough(mg/L)63721165151.5 g twice daily15.784631164071 g once daily12.37355444391 g twice daily11.87154102444850 mg once daily14.76745324481 g twice daily11.059711904811.5 g once daily13.436109864481 g twice daily13.984551385660.5 g once daily18.34567662991 g 8 hourly7.0AUC, Area Under the Curve Table 4Characteristics and vancomycin dosing of patients monitored by AUCAge (years)Weight (kg)Baseline Serum Creatinine (µmol/L)AUC (mg·h/L)Dose RegimenTrough(mg/L)63721165151.5 g twice daily15.784631164071 g once daily12.37355444391 g twice daily11.87154102444850 mg once daily14.76745324481 g twice daily11.059711904811.5 g once daily13.436109864481 g twice daily13.984551385660.5 g once daily18.34567662991 g 8 hourly7.0AUC, Area Under the Curve Characteristics and vancomycin dosing of patients monitored by AUC AUC, Area Under the Curve Discussion This study demonstrates the real-world implementation of a hybrid vancomycin dosing strategy incorporating revised trough targets, with selective use of a non-Bayesian AUC. The intervention was associated with a significant reduction in supratherapeutic concentrations (11% vs. 20%, p < 0.01) and lower cumulative exposure at 72 h (83 vs. 104 mg/kg, p < 0.01), alongside a numerical, though not statistically significant, reduction in AKI. These improvements were achieved without bacteraemia recurrence in the QIP cohort and without an increase in in-hospital mortality, supporting the safety of the approach. Operationally, vancomycin concentrations were monitored less frequently in the QIP cohort, while the number of dose adjustments remained similar. Collectively, the findings support a feasible strategy for optimizing vancomycin use and provide a model for broader clinical adoption. Revision of vancomycin trough targets was prompted by observations from a parallel urinary biomarker study [3] that identified a notable incidence of severe AKI among patients treated with vancomycin. Case review suggested that efforts to achieve traditional trough targets of 15–20 mg/L, particularly in indications such as skin and soft tissue or urinary tract infections, may have contributed to nephrotoxicity. In our study, 6 of 9 patients undergoing AUC-guided dosing achieved therapeutic AUC with trough concentrations < 15 mg/L. This is consistent with the meta-analysis by Lim et al. who reported that the median troughs in the AUC-based group were often lower and less than 15 mg/L [19]. A retrospective study by Chen et al. also concluded that troughs of 15–20 mg/L often resulted in an AUC that was greater than necessary for therapeutic efficacy [11]. The correlation may vary across populations [20]. The broader trough target of 10-20 mg/L is also consistent with prior vancomycin dosing studies and implementation work [13, 21, 22]. Safety considerations are important when interpreting vancomycin dosing strategies. In our study, in-hospital mortality in the QIP cohort was lower compared with the historical group, although this was not statistically significant (3.5% vs. 7.5%, p = 0.54). While improved vancomycin exposure in the QIP cohort may contribute to reduced AKI, and AKI itself is associated with increased length of stay and mortality, the influence of vancomycin concentration on mortality is likely modest compared with other clinical factors such as infection severity or comorbidities. Mortality was therefore assessed primarily as a safety outcome, balancing risk of AKI with the need for adequate antimicrobial therapy, particularly as a study in enterococcal infection reported that vancomycin trough of less than 15 mg/L was associated with higher 30-day mortality [5]. In our QIP cohort, subtherapeutic concentrations were slightly more frequent (17% vs. 12%, p = 0.07), likely reflecting a more conservative dosing approach following the expansion of the trough target to 10-20 mg/L; however, this was accompanied by a reduction in supratherapeutic trough concentrations. Importantly, our protocol requested higher trough targets (15–20 mg/L) were retained for severe infections, as specified in the institutional guideline. Our study adopted a hybrid approach with selective implementation of AUC-guided dosing. Among 22 patients in the pilot wards where trained pharmacists were available, 9 received AUC-based dosing according to a predefined algorithm. We excluded those with baseline serum creatinine>180µmol/L. This cutoff aligns with prior AUC-based vancomycin studies that excluded patients with baseline serum creatinine > 2.0 mg/dL [23, 24]. We also excluded patients with a > 25% change in serum creatinine within 3 days, reflecting a pragmatic threshold to identify “unstable” renal function in the inpatient setting, where serum creatinine may be influenced by hydration status, muscle wasting, and prolonged hospitalization. Even smaller fluctuations in creatinine have been associated with worse long-term renal outcomes in drug-induced AKI [25]. Because AUC monitoring may be less reliable under these circumstances, conservative criteria were adopted for the pilot phase. Among the small subset of patients who received AUC-guided dosing, 1 of 9 (11%) developed AKI, compared with 18% in the historical cohort and 13% among QIP patients receiving trough-based dosing. This observation is broadly consistent with a prior non-Bayesian AUC study [26], although reported AKI incidence varies across studies [19, 27]. Interpretation of these findings is limited by the study design and small AUC sample size. As with most inpatient studies, AKI is multifactorial and may be influenced by sepsis, hemodynamic instability, and concomitant nephrotoxins, which may contribute to the differences in AKI incidence across studies. One of the barriers in adopting a universal AUC-based TDM approach is the logistical challenge of additional peak concentrations, as well as the costs associated with extra monitoring. Meng et al. estimated that a universal AUC-based approach in a 613-bed hospital could increase annual costs by up to USD$49,000 due to the additional peak concentrations [13]. However, two retrospective cohort studies found that the total cost of vancomycin therapy, including drug, laboratory, nursing and pharmacist costs, was similar between trough-based and AUC-guided approaches [28, 29]. Alsowaida et al. further showed that electronic health record (EHR)-integrated Bayesian AUC estimation improved operational efficiency as compared with first-order pharmacokinetic equations, with vancomycin concentrations more likely to be usable for AUC calculations [15]. Such EHR-based approaches may help reduce logistical challenges in AUC implementation. In our study, the monitoring frequency of vancomycin concentration was significantly lower in the QIP cohort. One possible explanation could be that our hybrid approach tends to avoid supratherapeutic concentrations, which often prompt more drug concentrations being drawn. In an exploratory analysis within the QIP cohort, the frequency of vancomycin concentration monitoring (including both trough and peak measurements) was lower in AUC-guided patients. Dose adjustments were also less frequent in the AUC group. This finding aligns with two quasi-experimental studies which found that patients undergoing AUC-based monitoring tended to require fewer dose adjustments compared to trough-based monitoring [30, 31]. We acknowledge several limitations in our pilot study. The limited sample size reduced our ability to demonstrate a reduction in nephrotoxicity or mortality. In addition, the small number of patients receiving AUC-guided dosing limits interpretation of its specific contribution within this hybrid implementation model. Vancomycin trough concentrations were categorized broadly as subtherapeutic, therapeutic, or supratherapeutic (using 10 and 20 mg/L as cutoffs), and more granular distributions (e.g., 10–15 mg/L vs. 15–20 mg/L) were not captured, limiting detailed comparisons between groups. Bacteraemia status was not systematically captured in the historical cohort, limiting comparisons across groups. Baseline nephrotoxin use was not captured, and pathogen-specific analyses were not performed. We did not account for the potential additional time required by pharmacists to manage both AUC- and trough-based monitoring, as this was not designed as a cost-effectiveness study. Future work will explore the use of a Bayesian calculator for AUC dosing, incorporate additional demographic and disease severity data to account for confounders for AKI development, and examine the relationship between cumulative vancomycin exposure and long-term renal outcomes. Despite these limitations, our study provides valuable insights into the hybrid approach of a revised vancomycin dosing strategy, demonstrating its safety, practicality, and efficacy in therapeutic vancomycin management. We plan to implement this approach hospital-wide further to assess its impact on nephrotoxicity and other efficacy outcomes. Conclusion We demonstrated that the hybrid dosing strategies implemented in the QIP, including revision of trough targets to 10–20 mg/L and selective incorporation of AUC-guided dosing, were associated with reduced supratherapeutic vancomycin concentrations, as well as lower cumulative exposure at 72 h, with numerically lower AKI. This approach appeared safe and practical in routine inpatient care. However, the small number of patients receiving AUC-guided dosing limits interpretation of its specific contribution. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1